BovoLep Production Begins

Through market research, Bovogen Biologicals discovered that animal pharmaceutical manufacturers using BSA for the growth of a variety of micro-organism derived vaccines were constantly frustrated at the variability in the performance of cultures. Through development work with industry partners and customers, Bovogen developed a non-animal, synthetic lipid fortified BSA product  that demonstated advantages such as process and yield consistency, enhanced product yield and lipid content consistency. BovoLep BSA was also shown to be a far superior product in serum free mammalian culture systems when compared to traditional BSA products.

As a result of this collaboratoive effort, Bovogen commenced production of BovoLep BSA in mid-2004. 

For more information conatct Bovogen Biologicals.